Firebrick Pharma Limited (ASX: FBR) is an Australian-based biopharmaceutical company focused on developing novel treatments for cancer. The company's operations and projects are focused on developing small molecule therapeutics that target cancer stem cells, as well as on exploring innovative drug delivery technologies. Firebrick's objectives include producing medicines that are more effective, safer and more affordable than currently available treatments. Additionally, the company is committed to building a strong portfolio of products to meet unmet medical needs.